Clinical Manufacturing Site Approved for Molecular Profiles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Clinical Manufacturing Site Approved for Molecular Profiles


UK-based contract research and manufacturing organization Molecular Profiles has opened its new facility following a successful inspection from the Medicines and Healthcare products Regulatory Agency (MHRA). The Nottingham-based, pharmaceutical production site will provide clinical manufacturing capabilities.

This new facility marks a significant expansion for the company that started life as a spin-out from Nottingham University more than 15 years ago, the company reports. The investment adds six GMP suites, new laboratories, and a clinical packing area to support clients’ Phase I and II clinical trial projects.

The approval of the company’s cGMP-compliant facility follows a recent visit from Nick Clegg, Deputy Prime Minister of the UK Government, which provided £1.6m to the expansion through the regional growth fund grant. The new manufacturing site supports Molecular Profiles’ alliance with Onyx Scientific, which delivers pharmaceutical development services from drug discovery through the later phases of clinical development.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here